Advanced Code injection

Quebec companies will evaluate their technologies in Ontario hospitals

A recent agreement between the Ontario Bioscience Innovation Organization (OBIO®) and the Centre Québécois d'Innovation en Biotechnologie (CQIB) will enable Quebec companies to evaluate their technologies in real-world healthcare situations as part of OBIO's Early Adopter Health Network (EAHN™).

EAHN™ brings together health technology companies and organizations in a collaborative healthcare system to evaluate, refine, adopt and procure Canadian-made technology solutions. By joining EAHN™, CQIB will become the first Quebec incubator of EAHN™ and will play a role in helping Canada's healthcare ecosystem improve patient care. As part of the partnership agreement, CQIB will identify companies in its network that are a potential fit for EAHN™ and exclusively evaluate and pre-qualify Quebec companies so they can access EAHN™.

"We are very pleased to welcome CQIB to OBIO's EAHN™ and to share our expertise in supporting Quebec and Canadian companies to improve the adoption of innovation in Ontario's healthcare facilities," says Maura Campbell, President and CEO of OBIO®.

"Thanks to EAHN™, Quebec companies supported by CQIB and its Medxlab program will gain easier access to funding for technical and commercial validation of their technologies. They will benefit from their collaboration with Ontario's healthcare institutions and OBIO's expertise. Also, we will facilitate Ontario companies' access to the Quebec healthcare network as well as the use of our co-working space", says Perry Niro, CEO of the CQIB.